Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials-Reference-Cited by-同舟云学术

Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials

Published:2016-07 Issue: Volume:61 Page:111-121
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Roviello Giandomenico,Sigala Sandra,Sandhu Shahneen,Bonetta Alberto,Cappelletti Maria Rosa,Zanotti Laura,Bottini Alberto,Sternberg Cora N.,Fox Stephen B.,Generali Daniele

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference40 articles.

1. Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths;Neppl-Huber;Ann Oncol,2012

2. Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics;Mukherji;Cancer Metastasis Rev,2014

3. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011

4. AFFIRM investigators increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

5. Abiraterone in metastatic prostate cancer without previous chemotherapy;Ryan;N Engl J Med,2013

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting prostate cancer via therapeutic targeting of PIM-1 kinase by Naringenin and Quercetin;International Journal of Biological Macromolecules;2024-09

2. Evaluation of a photodynamic therapy agent using a canine prostate cancer model;The Prostate;2023-05-21

3. Imageological/Structural Study regarding the Improved Pharmacokinetics by 68Ga-Labeled PEGylated PSMA Multimer in Prostate Cancer;Pharmaceuticals;2023-04-14

4. Multi-omics biomarkers aid prostate cancer prognostication;2022-09-22

5. Proteomics reveals MRPL4 as a high‐risk factor and a potential diagnostic biomarker for prostate cancer;PROTEOMICS;2022-09-18